bioRxiv · 10.1101/2023.06.26.546571
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones
Abstract
Intratumoral cellular heterogeneity necessitates multi-targeting therapies for improved clinical benefits in patients with advanced malignancies. However, systematic identification of patient-specific treatments that selectively co-inhibit cancerous cell populations poses a combinatorial challenge, since the number of possible drug-dose combinations vastly exceeds what could be tested in scarce patient cells. Here, we developed scTherapy, a machine learning model that leverages single-cell transcriptomic profiles to prioritize multi-targeting treatment options for individual patients with hematological cancers or solid tumors.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ianevski, A., Nader, K., Bulava, D., Giri, A. K., Ruokoranta, T., Kuusanmaki, H., Ikonen, N., Sergeev, P., Vaha-Koskela, M., Vaharautio, A., Kontro, M., Porkka, K., Heckman, C. A., Wennerberg, K., Aittokallio, T.. 2023-06-28. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones. https://doi.org/10.1101/2023.06.26.546571
Cite the original work for its findings. Save a collection to share your selection of sources.